title: Oxidative stress from rapid versus slow intravenous iron replacement in haemodialysis patients.
abstract: RESULTS
  Oxidative stress was examined in 19 erythropoietin-treated haemodialysis patients who were receiving 100 mg of iron sucrose every 2 weeks by two intravenous methods, rapid injection and slow infusion. There were no significant differences in incidence of iron oversaturation state between the two methods. Regarding oxidative stress markers, the values of plasma and red blood cell thiobarbituric acid reactive substances (TBARS) expressed in terms of malonyldialdehyde (MDA) equivalents following the two methods did not increase, and the values of area under the curve (AUC) of both markers were not different between both regimens. Also, there were no significant differences in the values of plasma and AUC of anti-oxidant markers including total anti-oxidant status, reduced thiols, and vitamin E among both periods treated with two intravenous iron methods.
  
  
  CONCLUSIONS
  As such, both intravenous iron methods could be safely used without enhancing oxidative stress in haemodialysis patients. The rapid injection method would be the preferred method of intravenous iron administration because it is more convenient while still retaining the safety profile.
authors.affiliation: Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand.
authors.forename: Khajohn
authors.initials: K
authors.lastname: Tiranathanagul
authors.forename: Somchai
authors.initials: S
authors.lastname: Eiam-Ong
authors.forename: Piyaratana
authors.initials: P
authors.lastname: Tosukhowong
authors.forename: Kearkiat
authors.initials: K
authors.lastname: Praditpornsilpa
authors.forename: Kriang
authors.initials: K
authors.lastname: Tungsanga
mesh_terms: D000975:Antioxidants / Q000378:metabolism; D018592:Cross-Over Studies; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D011994:Recombinant Proteins; D006435:Renal Dialysis; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
chemical_list: D000975:Antioxidants; D005290:Ferric Compounds; D011994:Recombinant Proteins; D017392:Thiobarbituric Acid Reactive Substances; D004921:Erythropoietin; D008315:Malondialdehyde; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid